TABLE 2.
Results: Primary and Secondary Outcomes in unvaccinated patients.
| Outcomes | Total no. | Received fluvoxamine | Not- received fluvoxamine | Relative risk ratio, p value, 95% CI |
|---|---|---|---|---|
| Total | Number (Percent) | Number (Percent) | ||
| Unvaccinated patients | 299 | 242 (80.9%) | 57 (19.1%) | |
| Primary outcomes | ||||
| 30-day mortality | 5 | 1 (0.4%) | 4 (7.0%) | RR 0.06, p = 0.011, 95% CI 0.007 to 0.516 |
| Hospitalization | 34 | 23 (9.5%) | 11 (19.3%) | RR 0.49, p = 0.035, 95% CI 0.26–0.95 |
| Secondary outcomes | ||||
| Oxygen requirement | 28 | 15 (6.2%) | 13 (22.8%) | RR 0.27, p < 0.001, 95% CI 0.14–0.54 |
| Tocilizumab | 10 | 5 (2.0%) | 5 (9.0%) | RR 0.49, p = 0.152, CI 0.17–1.31 |
| Days in hospital | 12 days | 7 days | Δ 5 days, p 0.08, CI −0.63 to 10.63 | |